Correlates of delayed disease progression in HIV-1-infected Kenyan children

Journal of Immunology

Volumn 174, Issue 12, 2005, Pages 8191-8199

  Chakraborty, Rana ^a   Morel, Anne Sophie ^c   Sutton, Julian K ^b   Appay, Victor ^b   Ripley, Ruth M ^d   Dong, Tao ^b   Rostron, Tim ^b   Ogola, Simon ^e   Palakudy, Tresa ^f   Musoke, Rachel ^e   D'Agostino, Angelo ^f   Ritter, Mary ^c   Rowland Jones, Sarah L ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF NAIROBI   (Kenya)

^f Nyumbani Children's Home   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; GENOMIC DNA; HLA ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ALLELE; ANTIGEN EXPRESSION; ARTICLE; CHILD; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA TYPING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KENYA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS DIAGNOSIS; VIRUS INFECTION;

EID: 20444426244     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.12.8191     Document Type: Article

References (54)

1. Taha, T. E., S. M. Graham, N. I. Kumwenda, R. L. Broadhead, D. R. Hoover, D. Markakis, L. van Der Hoeven, G. N. Liomba, J. D. Chiphangwi, and P. G. Miotti. 2000. Morbidity among HIV-1-infected and uninfected African children. Pediatrics 106: E77.
2. Goulder, P. J., P. Jeena, G. Tudor-Williams, and S. Burchett. 2001. Paediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management. Br. Med. Bull. 58: 89-108.
3. Deacon, N. I., Tsykin, A., Solomon A. et al. 1995. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270: 988-991.
4. Cao, Y., L. Qin, L. Zhang, J. Safrit, and D. D. Ho. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332: 201-208.
5. Klein, M. R., S. H. Van der Burg, E. Hovenkamp, A. M. Holwerda, J. W. Drijfhout, C. J. Melief, and F. Miedema. 1998. Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. J. Gen. Virol 79(Pt. 9): 2191-2201.
6. Carrington M., G. W. Nelson, M. P. Martin, T. Kissner, D. Vlahov, J. J. Goedert, R. Kaslow, S. Buchbinder, K. Hoots, and S. J. O'Brien. 1999. HLA and HIV-1: heterozygote advantage and B35-Cw04 disadvantage. Science 283: 1748-1752.
7. + cell numbers and clinical staging. J. Clin. Invest. 84: 1892-1899.
8. Musey, L. K., J. N. Krieger, J. P. Hughes, T. W. Schacker, L. Corey, and M. J. McElrath. 1999. Early and persistent human immunodeficiency virus type I (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J. Infect. Dis. 180: 278-284.
9. Rosenberg, E. S., J. M. Billingsley, A. Caliendo, S. L. Boswell, P. E. Sax, S. A. Kalams, and B. D. Walker. 1997. Vigorous HIV-1 specific CD4 T-cell responses associated with control of viremia. Science 278: 1447-1450.
10. Wu, L.. W. A. Paxton, N. Kassam, N. Ruffing, J. B. Rottman, N. Sullivan, H. Choe, J. Sodroski, W. Newman, R. A. Koup, and C. R. Mackay. 1997. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1 in vitro. J. Exp. Med. 185: 1681-1691.
11. John, G. C., T. Bird, J. Overbaugh, R. Nduati, D. Mbori-Ngacha, T. Rostron, T. Dong, L. Kostrikis, B. Richardson, and S. L. Rowland-Jones. 2001. CCR5 promoter polymorphisms in a Kenyan Perinatal Human Immunodeficiency Virus Type 1 Cohort: association with increased 2-year maternal mortality. J. Infect. Dis. 184: 89-92.
12. Anzala, A. O., T. B. Ball, T. Rostron, S. J. O'Brien, F. A. Plummer, and S. L. Rowland-Jones. 1998. CCR2-641 allele and genotype association with delayed AIDS progression in African women. Lancet 351: 1632-1633.
13. Caakraborty, R., R. Musoke, T. Palakudy, A. Cross, and A. D'Agostino. 2003. Management of severely immunocompromised human immunodeficiency virus type 1-infected African orphans with structured treatment interruption: another kind of salvage therapy, Clin. Infect. Dis. 36: 1483-1485.
14. Bunce, M., C. M. O'Neill, M. C. Barnado, P. Krausa, M. J. Browning, P. J. Morris, and K. I. Welsh. 1995. Phototyping: comprehensive DNA typing for HLA-A, B, C DRB1, DRB3, DRB4, DRB5 and DQBB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46: 355-367.
15. + lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J. Clin. Invest. 107: 1303-1310.
16. Ogg, G. S., X. Jin, S. Bonhoeffer, P. Moss, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, A. Hurley, et al. 1999. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 73: 797-800.
17. Douek, D. C., R. D. McFarland, P. H. Keiser, E. A. Gage, J. M. Massey, B. F. Haynes, M. A. Polis, A. T. Haase, M. B. Feinberg, J. L. Sullivan, et al. 1998. Changes in thymic function with age and during the treatment of HIV infection. Nature 396: 690-695.
18. Altman, J., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. [Published erratum in 1998 Science 280: 1821.] J Science 274: 94-96.
19. + Tcell responses in young HIV-1-infected infants. J. Immunol. 167: 7134-7140.
20. + T cell responses to CMV in HIV-1-infected subjects. Virology 279: 459-470.
21. + T cells vary in differentiation phenotype in different persistent vims infections. Nat. Med. 8: 379-385.
22. + T cells produce antiviral cytokines but are impaired incytolytic function. J. Exp. Med. 192: 63-75.
23. + T cell proliferation is coupled to perform expression and is maintained in nonprogressors. Nat. Immunol 3: 1061-1068.
24. Giorgi, J. V., L. E. Hultin, J. A. McKeating, T. D. Johnson, B. Owens, L. P. Jacobson, R. Shih, J. Lewis, D. J. Wiley, J. P. Phair, S. M. Wolinsky, and R. Detels. 1999. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. infect. Dis. 179: 859-870.
25. Carbone, J., J. Gil, J. M. Benito, and E. Fernandez-Cruz. 2003. Decreased expression of activation markers on CD4 T lymphocytes of HIV-infected long-term non-progressors. AIDS 17: 133-134.
26. Diaz, M., D. C. Douek, H. Valdez, B. J. Hill, D. Peterson, I. Sanne, P. J. Piliero, R. A. Koup, S. B. Green, S. Schnittman, and M. M. Lederman. 2003. T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment. AIDS 17: 1145-1149.
27. McFarland, R. D., D. C. Douek, R. A. Koup, and L. J. Picker. 2000. Identification of a human recent thymic emigrant phenotype. Proc. Natl. Acad. Sci. USA 97: 4215-4220.
28. Geleziunas, R., W. Xu, K. Takeda, H. Ichijo, and W. C. Greene. 2001. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 410: 834-838.
29. + T cells. Eur. J. Immunol. 12: 3513-3524.
30. Vigano, A., M. Pinti, M. Nasi, L. Moretti, F. Balli, C. Mussini, D. Bricalli, N. Sala, R. Bugarini, S. Vella, N. Principi, and A. Cossarizza. 2001. Markers of cell death-activation in lymphocytes of vertically HIV-infected children naive to highly active antiretroviral therapy: the role of age. J. Allergy Clin. Immunol. 108: 439-445.
31. Nathan, L. M., L. M. Nerlander, J. Dixon, R. M. Ripley, R. Barnabas, B. E. Wholeben, R. Musoke, T. Palakudy, A. D'Agostino, and R. Chakraborty. 2003. Growth, morbidity and mortality in a cohort of institutionalised HIV-1-infected African children. J. Acquir. Immune Defic. Syndr. 34: 237-241.
32. 1994. Natural history of vertically-acquired HIV-1 infection: the European collaborative study. Pediatrics 94: 815-819.
33. Abrams, E. J., J. Weedon, R. W. Steketee, G. Lambert, M. Bamji, T. Brown, M. L. Kalish, E. E. Schoenbaum, P. A. Thomas, and D. M. Thea. 1998. Association of HIV load in early life with disease progression among HIV-infected infants. New York City Collaborative Study Group. J. Infect. Dis. 178: 101.
34. + T cell compartment. J. Immunol. 170: 4403-4410.
35. + T lymphocyte response to viral infection during fetal life. J. Clin. Invest. 111: 1747-1755.
36. Mofenson, L. M., J. Korelitz, W. A. Meyer, 3rd, J. Bethel, K. Rich, S. Pahwa, J. Moye, Jr., R. Nugent. and J. Read. 1997. The relationship between serum HIV-1 RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J. Infect. Dis. 175: 1029-1038.
37. Pontesilli, O., M. R. Klein, S. R. Kerkhof-Garde, N. G. Pakker, de F. Wolf, H. Schuitemaker, and F. Miedema. 1997. Kinetics of immune functions and virus replication during HIV-1 infection. Immunol. Lett. 57: 125-130.
38. Shearer, W. T., T. C. Quinn, P. LaRussa, J. F. Lew, L. Mofenson, S. Almy, K. Rich, E. Handelsman, C. Diaz, M. Pagano, V. Smeriglio, and L. A. Kalish. 1997. Viral load and disease progression in infants infected with HIV-1. Women and Infants Transmission Study Group. N. Engl. J. Med. 336: 1337-1342.
39. Xu, X. N., B. Laffert, G. R. Screaton, M. Kraft, D. Wolf, W. Kolanus, J. Mongkolsapay, A. J. McMichael, and A. S. Baur. 1999. Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor ζ chain. J. Exp. Med. 189: 1489-1496.
40. Fackler, O. T., and A. S. Baur. 2002. Live and let die: Nef functions beyond HIV replication. Immunity 16: 493-497.
41. Kirchhoff, F., P. J. Easterbrook, N. Douglas, M. Troop, T. C. Greenough, J. Weber, S. Carl, J. L. Sullivan, and R. S. Daniels. 1999. Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. J. Virol. 73: 5497-5508.
42. Bhardwaj, N., and B. D. Walker. 2003. Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine. Nat. Med. 9: 13-14.
43. + T cells. Nature 417: 95-98.
44. Douek, D. C., R. A. Koup, R. D. McFarland, J. L. Sullivan, and K. Luzuriaga. 2000. Effect of HIV on thymic function before and after antiretroviral therapy in children. J. Infect. Dis. 181: 1479-1482.
45. Chavan, S., B. Bennuri, M. Kharbanda, A. Chandrasekaran, S. Bakshi, and S. Pahwa. 2001. Evaluation of T cell receptor gene rearrangement excision circles after antiretroviral therapy in children infected with human immunodeficiency virus. J. Infect. Dis. 183: 1445-1454.
46. Franco, J. M., A. Rubio, M. Martinez-Moya, M. Leal, E. Merchante, A. Sanchez-Quijano, and E. Lissen. 2002. T cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood 99: 3702-3706.
47. Gibb, D. M., A. Newberry, N. Klein, A. de Rossi, I. Grosch-Woerner, and A. Babiker. 2000. Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Lancet 355: 1331-1332.
48. Resino, S., R. Correa, J. M. Bellon, and M. A. Munoz-Fernandez. 2003. Preserved immune system in long-term asymptomatic vertically HIV-1 infected children. Clin. Exp. Immunol 132: 105-112.
49. + T cell receptor repertoire perturbations with normal levels of T cell receptor excision circles in HIV-infected, therapy-naive adolescents. AIDS Res. Hum. Retroviruses 19: 487-495.
50. + T helper and a T-killer cell. Nature 393: 474-478.
51. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor. N. Engl. J. Med. 333: 1038-1044.
52. Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188: 2205-2513.
53. + T cells in individuals receiving highly active antiretroviral therapy (HAART). J. Immunol. 162: 1780-1788.
54. Papagno, L., V. Appay, J. Sutton, T. Rostron, G. M. Gillespie, G. S. Ogg, A. King, A. T. Makadzanhge, A. Waters, C. Balotta, et al. 2002. Comparison between HIV- and CMV-specific T cell responses in long-term HIV infected donors. Clin. Exp. Immunol. 130: 509-517.